Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates ...

Hims & Hers and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On June 23, 2025, Novo Nordisk announced ...

With the guidance of dermatologists, we tested over 25 anti-chafing sticks to most comfortable and effective options out ...

Discover why Hims & Hers Health's subscriber growth, profitability, and telehealth expansion make it a strong buy with a ...

Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit.

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Most investors have noticed that most stocks in the healthcare sector have declined to levels not seen in a while, making ...

U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right stocks for your investing style ...

Josh Nathan-Kazis is a senior writer at Barron's, covering the healthcare industry. He is a former staff writer at the Forward, where he investigated nonprofits, covered local and national politics, ...